eTRANSAFE

Enhacing TRANslational SAFEty Assessment through Integrative Knowledge Management
eTRANSAFE logo

FACTS & FIGURES

Start Date
End Date
Call
IMI2 - Call 9
Grant agreement number
777365

Type of Action: 
RIA (Research and Innovation Action)

Contributions
IMI Funding
20 000 000
EFPIA in kind
1 700 050
Other
0
Total Cost21 700 050

Summary

Assessing the safety of potential medicines remains immensely challenging. One major difficulty is understanding how well toxicity in animal tests predicts toxicity in humans. A lot of data on toxicity exists, but it is scattered across diverse public and private sources and stored in different formats.

The goal of the eTRANSAFE project is to develop a powerful data integration infrastructure (the Knowledge Hub) and use this as the basis for computer-based tools for use in drug development. The infrastructure would be flexible and expandable, and would draw on the latest technologies to deliver advanced solutions for data sharing, interoperability and exploitation. An ‘honest broker’ will ensure that confidential data would remain confidential, and overarching policies and guidelines will address ethical and legal issues such as the secondary use of human data. A large part of the project will be devoted to the creation of in silico (computer-based) tools for data mining and visualisation and, crucially, the prediction of potential toxicity.

The project outputs will increase the efficiency of preclinical toxicity studies, most notably in the pharmaceutical industry, and this in turn will help to speed up drug development. In addition, as the tools are computer-based, their use will contribute to a reduction in the use of animals in research. Finally, the project will contribute to the FAIR (‘findable, accessible, interoperable, re-useable) data principles.

Participants Show participants on map

EFPIA companies
  • AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany
  • AstraZeneca AB, Södertälje, Sweden
  • Bayer Aktiengesellschaft, Leverkusen, Germany
  • Boehringer Ingelheim International GmbH, Ingelheim, Germany
  • Clarivate Analytics (Uk) Limited, London, United Kingdom
  • F. Hoffmann-La Roche Ltd, Basel, Switzerland
  • Institut De Recherches Internationales Servier, Suresnes, France
  • Janssen Pharmaceutica NV, Beerse, Belgium
  • Merck KGaA, Darmstadt, Germany
  • Novartis Pharma AG, Basel, Switzerland
  • Sanofi-Aventis Research and Development, Chilly Mazarin, France
Universities, research organisations, public bodies, non-profit groups
  • Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands
  • European Molecular Biology Laboratory, Heidelberg, Germany
  • Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V., München, Germany
  • Fundació Institut Mar d’investigacions Mèdiques (IMIM), Barcelona, Spain
  • Lhasa Limited, Leeds, United Kingdom
  • Liverpool John Moores University, Liverpool, United Kingdom
  • Simcyp Limited, London, United Kingdom
  • Universitat Pompeu Fabra, Barcelona, Spain
  • Universiteit Leiden, Leiden, Netherlands
  • Universität Wien, Vienna, Austria
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Molecular Networks GmbH – Computerchemie, Erlangen, Germany
  • Optibrium Limited, Cambridge, United Kingdom
  • Pds Computer Software Limited, Leicester, United Kingdom
  • Synapse Research Management Partners S.L, Barcelona, Spain
Third parties
  • Centro Nacional de Investigaciones Oncológicas, Madrid, Spain
  • Technical University of Denmark, Kgs. Lyngby, Denmark

CONTACT

Project coordinator
Ferran Sanz
Fundació Institut Mar d’Investigacions Mèdiques (IMIM)
Spain
+34 933160540
fsanz[at]imim.es